Get the Stockscreener App
1.94
2.11%
0.04
Pre-market:
1.95
0.01
+0.52%
Allogene Therapeutics Inc stock is traded at $1.94, with a volume of 5.78M.
It is up +2.11% in the last 24 hours and down -3.00% over the past month.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
See More
Previous Close:
$1.90
Open:
$1.93
24h Volume:
5.78M
Relative Volume:
0.58
Market Cap:
$669.60M
Revenue:
$22,000
Net Income/Loss:
$-173.76M
P/E Ratio:
-2.5257
EPS:
-0.7681
Net Cash Flow:
$-109.53M
1W Performance:
+4.86%
1M Performance:
-3.00%
6M Performance:
+31.97%
1Y Performance:
+44.78%
1-Day Range:
$1.93
$2.10
1-Week Range:
$1.75
$2.10
52-Week Range:
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.94 | 669.60M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-10-26 | Resumed | Jefferies | Buy |
| Jan-09-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Yahoo Finance
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio - Insider Monkey
A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test - The Business Journals
CMO Roberts to succeed Chang as Allogene CEO - BioCentury
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Allogene Therapeutics Names Zachary Roberts as New CEO - The Globe and Mail
Allogene Therapeutics, Inc. 8-K SEC Filing May 28, 2026: Company Details, Common Stock, and Exchange Information - Minichart
Allogene CEO to step down; Agios drug fails key test - BioPharma Dive
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Allogene Therapeutics (ALLO) Announces Leadership Transition - GuruFocus
Allogene Therapeutics names Zachary Roberts CEO in planned succession - MSN
Allogene Therapeutics names Zachary Roberts as new CEO By Investing.com - Investing.com South Africa
Allogene Therapeutics CEO David Chang Steps Down - marketscreener.com
Allogene Therapeutics announces planned CEO succession - marketscreener.com
Allogene Therapeutics names Zachary Roberts as new CEO - Investing.com
Zachary Roberts named Allogene President and CEO, David Chang stepping down - TradingView
Allogene Therapeutics (ALLO) elevates Zachary Roberts to CEO with major equity awards - Stock Titan
Allogene Therapeutics, Inc. Announces CEO Changes - marketscreener.com
Allogene Therapeutics (ALLO) Surges 6%: Can the Biotech Reclaim Key Resistance?On Balance Volume - thelegaladvocate.com
ALLO Stock Steadies As Cash Runway Extends To 2029 On Trial Progress - StocksToTrade
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer cell therapy firm Allogene lines up three investor talks - Stock Titan
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan
Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO) - The Globe and Mail
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 7.7%Here's What Happened - MarketBeat
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - The Globe and Mail
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):